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The HIV-1 capsid (CA) protein plays an important role in virus assembly and infectivity. Previously, we showed that Ala substitutions in the N-
terminal residues Trp23 and Phe40 cause a severely defective phenotype. In searching for mutations at these positions that result in a non-lethal
phenotype, we identified one candidate, W23F. Mutant virions contained aberrant cores, but unlike W23A, also displayed some infectivity in a
single-round replication assay and delayed replication kinetics in MT-4 cells. Following long-term passage in MT-4 cells, two second-site
mutations were isolated. In particular, the W23F/V26I mutation partially restored the wild-type phenotype, including production of particles with
conical cores and wild-type replication kinetics in MT-4 cells. A structural model is proposed to explain the suppressor phenotype. These findings
describe a novel occurrence, namely suppression of a mutation in a hydrophobic residue that is critical for maintaining the structural integrity of
CA and proper core assembly.
Published by Elsevier Inc.Keywords: HIV-1 capsid protein; Second-site suppressors; HIV-1 viral cores; Dominant-negative inhibition; HIV-1 assembly; Structural models; Reverse
transcriptase; Transmission electron microscopyIntroduction
The Gag polyprotein of human immunodeficiency virus
type-1 (HIV-1), also known as Pr55gag, is the only viral protein
required for particle assembly (Freed, 1998; Vogt, 1997; Wills
and Craven, 1991). During or shortly after budding, the viral
protease cleaves Gag into the mature HIV-1 proteins, which
include (from the N- to C-terminus): matrix; capsid (CA);
nucleocapsid (NC); and p6 (Freed, 1998; Swanstrom and Wills,
1997; Vogt, 1997). Proteolytic processing of Gag induces
dramatic structural rearrangements (virus “maturation”), which
lead to formation of mature, infectious HIV-1 virions containing⁎ Corresponding author. Fax: +1 301 496 0243.
E-mail address: levinju@mail.nih.gov (J.G. Levin).
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doi:10.1016/j.virol.2006.09.027electron-dense, cone-shaped cores (Gross et al., 1998, 2000;
von Schwedler et al., 1998; Wiegers et al., 1998).
The HIV-1 core has been likened to a fullerene cone
(Benjamin et al., 2005; Briggs et al., 2006; Ganser et al., 1999;
Li et al., 2000) and is assembled with hexameric arrays of N-
terminal CA domains such that each hexamer is connected to
six others by interactions with C-terminal CA dimers (Ganser et
al., 1999, 2003; Ganser-Pornillos et al., 2004; Huseby et al.,
2005; Lanman et al., 2003; Lanman and Prevelige, 2005; Li et
al., 2000; Mayo et al., 2003). Helices I and II line the inner holes
of each hexameric ring and are important for holding the rings
together (Ganser-Pornillos et al., 2004; Lanman et al., 2003; Li
et al., 2000). Based on the N-terminal domain structure of
murine leukemia virus (MuLV) CA, it has been suggested that
helix III also participates in the formation of the inner lining of
Fig. 1. Ribbon diagram highlighting helices I, II, III, and VII in the N-terminal
domain of HIV-1 CA. The ribbon diagram shows a top view of helices I, II, III,
and VII in the N-terminal domain structure. The positions of two conserved
hydrophobic residues Trp23 (helix I) and Phe40 (helix II) are shown. The
positions of Val26 (helix I), Val59 (helix III), as well as I134 and I135 (helix VII)
are also illustrated in the figure.
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numerous studies supports the idea that proper assembly of
conical cores is required for HIV-1 infectivity (Auerbach et al.,
2006; Dorfman et al., 1994; Fitzon et al., 2000; Forshey et al.,
2002; Reicin et al., 1996; Scholz et al., 2005; Tang et al., 2003a,
2001; von Schwedler et al., 1998, 2003).
The mature HIV-1 CA protein consists of 231 residues,
which are folded into two independent domains connected by a
short linker (Freed, 1998): an N-terminal “core” domain
(residues 1–145) (Gitti et al., 1996; Momany et al., 1996;
Tang et al., 2002) and a C-terminal “dimerization” domain
(residues 151–231) (Gamble et al., 1997). In general, mutation
of N-terminal residues does not interfere with particle
production, but mutant virions often exhibit defects in reverse
transcription and core assembly as well as loss of infectivity
(Tang et al., 2003b and references therein; Auerbach et al.,
2006; Rulli et al., 2006; Scholz et al., 2005).
In earlier work, we found that Ala substitutions at Trp23
(helix I) and Phe40 (helix II), members of a conserved group
of N-terminal hydrophobic residues in HIV-1 CA (Momany et
al., 1996), result in a postentry defect with the following
phenotype: virions produced are noninfectious, have aberrant
cores, and are unable to initiate reverse transcription in
infected cells, despite the presence of a functional reverse
transcriptase (RT) in virus particles (Tang et al., 2001).
Additionally, mutant cores retain an excessive amount of CA
and contain almost no RT (Tang et al., 2003b). In view of
recent findings emphasizing the critical role of helices I and II
for CA structure and our data demonstrating the specific
importance of Trp23 and Phe40 for proper core assembly and
overall folding of CA, we initiated a study to provide new
information on the plasticity of CA, i.e., its ability to tolerate
change in residues crucial for CA structure without total
abrogation of biological activity. More specifically, we wanted
to determine (i) whether Trp23 or Phe40 can be changed to
other residues that would permit some retention of infectivity
and (ii) if so, whether the virus can rescue the mutant
phenotype by generating second-site suppressor mutations.
Here we report that a search for other substitutions at
positions 23 and 40, which could fulfil the requirement for some
viral infectivity, identified one such mutation, i.e., Trp23 to Phe.
Thus, W23F exhibits a low level of infectivity in a single-round
replication assay and delayed replication kinetics in MT-4 cells.
Isolation of second-site suppressor mutations in CA is rare and
might not occur in the case of a mutation that has a major effect
on CA structure. Yet surprisingly, long-term passage of W23F
in MT-4 cells led to isolation of two second-site mutations, one
of which, W23F/V26I (helix I), partially restores the wild-type
(WT) phenotype. A structural model that accommodates the
spatial changes induced by the W23F and V26I mutations
shows that hydrophobic interactions between Ile26 and Phe23
are possible and helps to explain the suppressor phenotype. The
data illustrate an unusual example in which a residue so
intimately involved in maintaining the structural integrity of CA
can be mutated without a complete loss of functional activity
and the mutation can be rescued, at least partially, by a second-
site suppression mechanism.Results
New mutations at positions 23 and 40 in the N-terminal
domain of CA
In earlier studies, we showed that mutants bearing Ala
substitutions for Trp23 and Phe40 (Fig. 1) have severe defects
in virus replication, virion ultrastructure, and biochemical
properties (Tang et al., 2001, 2003b). To further elucidate the
role of these residues in maintaining CA function, we asked
whether other substitutions besides Ala would result in a more
moderate phenotype. A total of 13 new mutations at Trp23
(W23C, D, F, G, H, L, M, N, P, S, T, V, and Y), two aromatic
substitution mutations at Phe40 (F40W and F40Y), and one
double mutation, W23F/F40W, were generated. The culture
supernatants from transfected HeLa cells were assayed for RT
activity, and virus production was found to be ∼60 to 90% of
the WT value (data not shown). However, when infectivity was
measured in a single-cycle assay using LuSIV cells (Roos et al.,
2000), only W23F displayed any infectivity, albeit at a very low
level (2% of the WT value) (see below); noninfectious mutants
had ∼0.5% of WT infectivity (data not shown).
The replication capacity of W23F was evaluated in long-
term culture experiments by transfecting T-cell lines, i.e., H9,
Jurkat, CEM (12D7), and MT-4 cells, with WT or W23F
plasmid DNAs. As expected, WT virus replicated at high levels
in all of these cell lines, with peak virus production reached
within the first week posttransfection (Fig. 2A; data not shown).
In contrast, W23F replicated only in MT-4 cells, but with
significantly delayed replication kinetics and a small peak of
virus production evident only on day 18 posttransfection (Fig.
2A; data not shown). This result could reflect the more
permissive nature of MT-4 cells, which are infected with HTLV-
Fig. 2. W23F phenotype. (A) Replication kinetics. MT-4 cells were transfected with WT and W23F plasmid DNAs. Cells were split 1:3 every 2 or 3 days. Virus
production was monitored by assaying RT activity in the culture supernatants for each time point. Symbols: WT, open squares; W23F, open triangles; mock, open
circles. (B) Incorporation of CypA into mature virus particles. HeLa cells were transfected with WT and W23F plasmid DNAs. Virion-associated proteins as well as
CypAwere detected by Western blot analysis, using anti-HIV RT and IN (Klutch et al., 1998) as well as anti-CA and anti-CypA (Tang et al., 2003b). The positions of
individual viral proteins and CypA are indicated to the left of the gel. (C) Retention of HIV-1 RT in WT and W23F viral cores. Virions isolated from the supernatant
fluids of transfected HeLa cells were treated with 0.3%NP-40 and were sedimented through 20% to 70% (wt/wt) linear sucrose gradients at 4 °C for 16 h at 120,000×g
in a Beckman SW55Ti rotor (Tang et al., 2003b). Twelve fractions were collected from the top of the gradient. The bar graph shows RT activity in the fractions
collected from WT (solid bars) or W23F (open bars) samples. (D) Retention of HIV-1 CA protein in viral cores. Detergent-treated virions were sedimented through
sucrose step gradients centrifuged at 4 °C for 60 min at 120,000×g in a Beckman SW55Ti rotor (Tang et al., 2003b). Five fractions were collected from top of the
gradients and were analyzed byWestern blot using AIDS patient sera. HIV-1 CA protein bands are shown. Fractions 1 and 2 represent the soluble and detergent-soluble
fractions, respectively. Fractions 3, 4, and 5 represent the detergent-resistant core fractions. The smaller band seen in W23F fractions 3 to 5 appears to be a CA
degradation product.
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to upregulate transcription of HIV-1 genes (Cheng et al., 1998;
Zack et al., 1988).
W23F phenotype
Since the replication data described above (Fig. 2A)
suggested that W23F might be less defective than W23A, it
was of interest to characterize the W23F phenotype in more
detail. Interestingly, like W23A and F40A (Tang et al., 2003b),
most of the new mutants were unable to incorporate normal
levels of CypA (data not shown). However, as illustrated in Fig.
2B, the protein composition of W23F was essentially the same
as that of WT and the ratio of CypA incorporated by W23F
relative to the level of integrase was 97% of the WT value.
It was also of interest to determine the amounts of RTand CA
retained in viral cores isolated by detergent treatment of virions
and subsequent sedimentation in sucrose density gradients(Tang et al., 2003b). As anticipated, the WT sample had two
peaks of RT activity, one in the soluble fractions 2 to 4, and the
other in the high-density core fractions 8 to 10 (Fig. 2C) (Tang
et al., 2003b). In contrast, like the original mutants W23A and
F40A (Tang et al., 2003b), W23F had only one peak of RT
activity, which was located in the soluble fractions 2 to 4 (Fig.
2C). Quantification of the data indicated that less than 5% of
total RT activity was retained in W23F cores, whereas ∼28% of
RT activity was detected in WT cores (also see Tang et al.,
2003b).
To examine CA content in viral cores, detergent-treated
virions were sedimented in a sucrose step gradient (Fig. 2D).
Proteins associated with viral cores were found primarily in
fraction 3, but some material was also detected in fractions 4
and 5 (Fig. 2D) (Tang et al., 2003b). The results of Western blot
analysis showed that the distribution of CA protein in the
sucrose fractions of W23F and WT samples was very similar.
Densitometry scanning of the CA bands showed that W23F
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lower than the values reported for W23A and F40A (∼70% of
total CA) (Tang et al., 2003b), but is still somewhat higher than
the WT value of ∼30% shown here and in a previous report
(Tang et al., 2003b) (see below).
The ultrastructure of W23F particles was investigated by
transmission electron microscopy. The images showed that WT
particles contained typical cone-shaped cores (Fig. 3A; Table
1), whereas the W23F virions had round, centric, or acentric
cores (defined in Table 1) and no conical cores (Fig. 3B; Table
1). Interestingly, the architecture of W23F resembles that of CA
mutant D51A (Tang et al., 2001; von Schwedler et al., 1998) but
is quite different from the abnormal ultrastructure seen with
W23A (Tang et al., 2001). In addition to the lack of conicalFig. 3. Transmission electron microscopy of WTand mutant virions produced in HeLa
W23F/V26I; (E) W23F/V26I/R154K. The arrows point to representative particles in
100 nm (A, B, and C) or 200 nm (D and E).cores, the diameter of W23F virions (183±40 nm) was
significantly larger than that of WT (125±13 nm) (compare
Figs. 3A and B; Table 1). These findings are consistent with rate
zonal sucrose density gradient sedimentation analysis (data not
shown) and are in accord with the conclusion that the CA
domain in Gag is a major determinant of virus size and
morphology (Ako-Adjei et al., 2005).
Taken together, the data demonstrate that, with the exception
of W23F, the new Trp23 and Phe40 mutations constructed in
this study had a severe impact on maintaining proper CA
structure and virus infectivity. In contrast, substitution of Phe at
position 23 led to a somewhat less defective phenotype with
respect to virion ultrastructure, incorporation of CypA, retention
of CA in viral cores, and even viral infectivity. Only the RTand MT-4 cells. HeLa cells: (A) HIV-1 WT; (B) W23F. MT-4 cells: (C) WT; (D)
the field with a WT phenotype (i.e., having conical cones). The scale bars are
Table 1
Electron microscopic analysis of HIV-1 WT and mutant particles in HeLa and MT-4 cells
Virus Cell type No. of
particles
Particle size
(nm)
No. of particles whose cores are
Cone-shaped Centric a Acentric b
WT HeLa 105 125±13 21 (20) c 53 (50) 31 (30)
W23F HeLa 82 183±40 0 28 (34) 66 (66)
WT MT-4 113 116±8.1 49 (43) 51 (45) 13 (12)
W23F/V26I MT-4 118 115±8.5 32 (27) 36 (31) 20 (17)
W23F/V26I/R154K MT-4 79 121±11 26 (33) 39 (49) 14 (18)
a Electron-dense cores that are centrally located in the particle.
b Electron-dense round cores that are pushed up against or close to the viral membrane.
c Numbers in parentheses are percentage of the total number of particles.
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W23A and F40A mutants.
W23F exhibits dominant-negative inhibition of WT infectivity
Since CA protein multimerizes (Campbell and Vogt, 1995;
Ehrlich et al., 1992; Ganser et al., 2003; Ganser-Pornillos et
al., 2004; Gross et al., 1997; Lanman et al., 2003; Mayo et
al., 2003; von Schwedler et al., 1998) when Gag molecules
assemble, we investigated the possibility that W23F and
W23A CA might affect the function of WT CA in trans and
thereby inhibit WT infectivity (Fig. 4). With a 5-fold excess
of WT:W23A DNA, viral infectivity was reduced to 36% of
the normal WT level, whereas with a 1:1 DNA ratio, the
resulting virus had only 1.3% of WT infectivity. With a 1:5
ratio for WT:W23A, infectivity was further reduced to 0.5%.
In contrast, W23F displayed a moderate inhibitory effect. At
a ratio of 5:1, the resulting virus population retained
significant infectivity (84% compared with WT alone) and
with 1:1 ratio, infectivity was 37% of the WT level.
Infectivity was reduced to 1.3% when there was a five-fold
excess of W23F DNA.
These findings indicate that the transdominant inhibitory
effect of W23A is ∼5-fold greater than that of W23F, in accord
with the greater severity of the observed W23A phenotype.Fig. 4. Dominant-negative activity of W23A and W23F. HeLa cells were
transfected with 5 μg of the following plasmid DNAs: WT alone, W23A or
W23F alone, and 5:1, 1:1, and 1:5 mixtures of WT and either W23A or W23F.
Virus stocks were harvested, normalized for RT activity, and used to infect
LuSIV cells (Roos et al., 2000). The values in the bar graph represent infectivity
as the percentage of the WT value, which was set at 100%. Here as well as in
Figs. 5 and 6, error bars indicate the standard deviation from at least three
independent experiments.Other HIV-1 (Furuta et al., 1997; Mammano et al., 1994; Scholz
et al., 2005; Shimano et al., 1998; Trono et al., 1989) and MuLV
(Rulli et al., 2006) CA mutants, which are capable of dominant-
negative interference, have also been described.
Second-site suppressors of W23F
The more moderate phenotype of W23F compared with that
of W23A (Figs. 2 and 4) and the ability of W23F to replicate in
MT-4 cells (Fig. 2A) encouraged us to try to isolate second-site
suppressor mutations by prolonged passage of W23F in MT-4
cells. For the initial infection and for each subsequent passage,
virions harvested at the peak of virus replication were used to
infect fresh MT-4 cells. The experiment was terminated when
the replication kinetics of the passaged virus were the same as
the kinetics for the WT. In all, four passaging cycles were
performed (data not shown).
The results of sequencing DNA samples collected at the time
of peak virus replication showed that viral DNA from each
passage retained the original W23F mutation. However, passage
3 DNA contained an additional mutation at nucleotide (nt) 1261
(G→A, codon change of GTA to ATA) that resulted in an Ile for
Val26 substitution (V26I); passage 4 DNA contained a third
mutation at nt 1646 (G→A, codon change of AGA to AAA)
that led to substitution of Arg for Lys at position 154 (R154K)
(data not shown). Val26 is located in helix I of the N-terminal
domain of HIV-1 CA and is close to Trp23 (Fig. 1), whereas
Lys154 is found at the beginning of the major homology region
(MHR) in the C-terminal domain. The emergence of the V26I
and V26I/R154K mutations in virions derived from long-term
passage of W23F in MT-4 cells suggests that the conversion
from delayed replication kinetics to WT kinetics is the
consequence of these additional mutations.
Defects in W23F are partially repaired by mutations V26I or
V26I/R154K
To further evaluate whether the two mutations, V26I and
V26I/R154K, were responsible for the improved replication
capacity of the W23F-derived virus, double (W23F/V26I) and
triple (W23F/V26I/R154K) mutants were constructed in a
pNL4-3 background (Adachi et al., 1986). Unlike the parental
clone W23F (Fig. 2A), the replication kinetics of W23F/V26I
and W23F/V26I/R154K in MT-4 cells exhibited a pattern close
110 S. Tang et al. / Virology 359 (2007) 105–115to that of WT (delay of only 2 days) (Fig. 5A). Furthermore, the
infectivity of the double and triple mutants in the single-cycle
LuSIV assay showed a modest increase from the value for
W23F (2% of WT infectivity) to 12% and 16% of the WT level
(virus produced in HeLa cells) and 14% and 17% (virus
produced in MT-4 cells), respectively (Fig. 5B). Similar results
were obtained when mutant virions isolated from transfected
MT-4 cells were tested in another single-cycle assay that uses
TZM-bl cells (data not shown). Thus, the second-site suppressor
mutations appeared to be capable of partial rescue of the
replication defect imposed by the W23F mutation.
We next sought to determine whether the suppressor
mutations could reverse the W23F core defects in RT and CA
content observed with particles produced in HeLa cells. As may
be seen in Fig. 5C, the amount of CA in the cores of these
mutants was ∼35% of total CA protein, which is close to the
WT value of ∼30% and lower than the value for W23F
(∼44%). Surprisingly, the amount of RT retained in W23F/
V26I and W23F/V26I/R154K cores was approximately theFig. 5. Phenotypes of second-site suppressor mutants. (A) WT proviral DNA and prov
MT-4 cells in a long-term culture experiment. RT activity in the culture supernatants w
squares), and W23F/V26I/R154K (open triangles). A mock-infected control (no D
supernatant fluids of transfected HeLa cells (black bars) andMT-4 cells (gray bars) we
are reported as percentage of WT infectivity, which was set at 100%. (C and D) Assa
described previously (Tang et al., 2003b). The amounts of CA in the detergent-resistan
recovered from the sucrose step gradient (C). RT activity in the core fractions isolate
plotted as the percentage of total RT activity (D). The values for WT and W23F insame as in W23F cores, i.e., around 5% of total RT activity (Fig.
5D). This does not appear to be the result of a defect in viral
protein expression, encapsidation, and processing since both the
double and triple mutants have protein profiles similar to that of
WT (data not shown). Taken together, these results demonstrate
that the phenotypes of the double and triple mutants are very
similar and represent a significant improvement in some, but not
all, aspects of the W23F defect.
Phenotypic analysis of CA mutations generated in the pNL4-3
WT clone
To examine the effects of the individual mutations that
appeared after long-term passage of W23F and, in particular, to
determine whether both the W26I and R154K mutations are
required for suppression, we constructed a series of single or
double mutations (Fig. 6). The single mutants V26I and R154K
as well as the double mutant V26I/R154K showed WTor nearly
WT replication kinetics in MT-4 cells, i.e., a replication peakiral DNAs bearing the indicated double or triple mutations were used to transfect
as assayed to monitor the replication of WT (closed circles), W23F/V26I (open
NA) was also included (open circles). (B) Virus particles obtained from the
re normalized and were used to infect LuSIV cells (Roos et al., 2000). The results
ys for detection of HIV-1 CA and RT retention in viral cores were performed as
t core fractions were quantified and plotted as the percentage of total CA protein
d from 20% to 70% (wt/wt) linear sucrose density gradients was quantified and
panels (C) and (D) were calculated from data in Fig. 2.
Fig. 6. Phenotypes of single or double CA mutants. (A) The replication kinetics of WT and the following CA mutants in MT-4 cells are shown: WT (closed circles),
V26I (open squares), R154K (open triangles), W23F/R154K (open circles) and V26I/R154K (open diamonds). (B) Virus infectivity was plotted as the percentage of
WT infectivity, which was set at 100%. Note that the data of Figs. 5A and 6A were obtained from the same experiment; thus, the WT curves in both figures are
identical.
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infectivity of these mutants measured in the single-cycle LuSIV
assay was between 82 and 120% of the WT level (Fig. 6B).
These results demonstrate that V26I, R154K, and the double
mutant V26I/R154K behave like WT, presumably because these
mutations do not affect CA function. However, the W23F/
R154K mutant failed to replicate in MT-4 cells (Fig. 6A) and
displayed only ∼2% of WT infectivity (Fig. 6B). This finding
taken together with the very slight (albeit consistent) improve-
ment in infectivity (Fig. 5B), CA content (Fig. 5C), and the
percentage of conical cores in the virus population (Table 1)
seen with the W23F/V26I/R154K mutant (compared with
W23F/V26I) suggests that the R154K mutation had only a
minimal effect on the second-site suppressor phenotype.
Ultrastructure of W23F/V26I and W23F/V26I/R154K virions
produced in MT-4 cells
Since the double and triple mutants exhibit close to WT
replication kinetics in MT-4 cells (Fig. 5A), it was also of
interest to determine whether these mutants exhibit WT virus
morphology. MT-4 cells transfected with either WT or the
double and triple mutants were fixed and examined by
transmission electron microscopy (Fig. 3). Interestingly, many
of the particles in each mutant sample (Figs. 3D and E)
resembled WT virions (Fig. 3C) and had conical cores (note
positions of arrows), which is consistent with the replication
data. Table 1 quantifies the distribution of different core
structures (cone-shaped, centric, or acentric) in the WT and
mutant samples. The percentage of cone-shaped cores in the
double and triple mutant samples was 27% and 33%,
respectively, compared to 43% for the WT. (The mutant values
were therefore 63% and 76%, respectively, of theWT value) The
particle sizes of the two mutants (double mutant, 115±8.5 nm;
triple mutant, 121±11 nm) were essentially the same as the size
of WT virions (116±8.1 nm) (Table 1). Thus, these findings
demonstrate that the second-site suppressor mutations largelyrestored proper assembly of virion cores and maturation of virus
particles in MT-4 cells.
Discussion
The goal of this study was to determine whether HIV-1 can
adapt to changes in residues that are important for maintaining
CA structure without losing all biological activity. Our
approach was to make mutant constructs that might retain
the ability to replicate and thereby present an opportunity to
isolate second-site suppressors. Out of 13 mutations in Trp23,
two in Phe40 (F40W, F40Y), and a double mutation (W23F/
F40Y), we found only one substitution, W23F, that could
satisfy this requirement. This observation emphasizes the
critical contribution of Trp23 and Phe40 to the local structure
of helices I and II, respectively. Note the proximity of these
residues in the view shown in Fig. 1 and the central location of
Phe in the hydrophobic core (Fig. 1).
The data clearly indicate a strict requirement for an aromatic
residue at position 23, and it is interesting that even Tyr cannot
substitute for Trp23 (or Phe40), presumably because the OH
group of Tyr makes it too hydrophilic. The finding that Trp
cannot replace Phe40 may reflect a steric requirement for a less
bulky residue at position 40. These results are consistent with
the crucial role of residues in helices I and II in the assembly of
the HIV-1 capsid (Ganser et al., 2003; Ganser-Pornillos et al.,
2004; Lanman et al., 2003; Li et al., 2000). In this regard, it is
also of interest to note that deuterium exchange studies have
identified a CA peptide consisting of residues 23 to 40, which
appears to be involved in N-terminal homotypic domain
interactions in the in vitro assembled CA protein as well as in
immature and mature HIV-1 virus-like particles (Lanman et al.,
2004; Lanman and Prevelige, 2005).
Isolation of second-site suppressors is a powerful genetic
technique to obtain additional insights into the structural and
functional effects of particular mutations. However, there are
only a few reports of second-site suppressors of CA mutations
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well tolerated (Auerbach et al., 2003; von Schwedler et al.,
2003) and the possibilities for suppressing these mutations may
be limited. Until now, second-site suppressors have been
described for CA mutations in (i) the HIV-1 CypA binding loop
(Aberham et al., 1996); (ii) an 11-residue segment (Guo et al.,
2005) at the C-terminus of HIV-1 CA that is required for virus
replication (Liang et al., 2002, 2003; Melamed et al., 2004); and
(iii) the RSV MHR (Bowzard et al., 2001).
In the present study, despite the low probability of success,
we were able to isolate two second-site suppressor mutants,
W23F/V26I and W23F/V26I/R154K, after prolonged passage
in MT-4 cells. However, it appears that only the V26I
substitution contributes significantly to suppression of the
W23F mutation (Fig. 6), although the additional R154K
mutation might have a subtle effect (Fig. 5 and Table 1). The
suppression event was specific for MT-4 cells since W23F
could not replicate even with delayed kinetics in other cell
lines (see above). Transmission electron microscopy showed
that many of the suppressor mutant particles isolated from MT-
4 cells have the appearance of WT virus and contain conical
cores (Figs. 3C–E; Table 1). Although the infectivity of these
mutants (produced in either HeLa or MT-4 cells) was higher
than that of W23F, it was still much lower than the WT value
(Fig. 5B). The reduced infectivity in CEM174 cells, which
are used in the LuSIV assay (Roos et al., 2000), might be
related to the fact that similar cells (CEM (12D7)) do not
support long-term replication of any of our mutants (data not
shown).
The original W23A and F40A mutants (Tang et al., 2003b)
and the HIV-1 His mutant, H84A (Scholz et al., 2005), were
found to have abnormally high amounts of CA in their cores. In
the case of W23F, the CA content is somewhat higher than
normal, but the amount of CA in the cores of the two second-site
suppressor mutants is essentially like that of WT, i.e., ∼30%
core-associated CA protein (Fig. 5C) (Tang et al., 2003b). (A
WT value of ∼17% has also been reported (Forshey and Aiken,Fig. 7. Structural models of WT CA and the W23F/V26I mutant illustrating contacts
residues. (A) WT. Model number 10 in the 1GWP.pdb structure file of the N-termina
(blue) and Val26 (magenta) side chains. Note that, for clarity, the terminal methyl gro
mutant. A possible model for the double mutant was constructed by mutating the Trp
Phe23 is shown in blue and Ile26 in magenta. This figure was kindly provided by S2003).) These data are in accord with recent physical
determinations indicating that, of the ∼5000 copies of Gag in
the immature virion, only 1000–1500 copies of CA are
associated with the core of the mature particle (Briggs et al.,
2003, 2004; Lanman et al., 2004; Vogt and Simon, 1999).
Another striking feature of W23A and F40A cores is a
reduction in RT content from the WT value of ∼30% of total
virion RT (Fig. 5D) (Khan et al., 2001; Tang et al., 2003b) to
∼5% (Tang et al., 2003b). Similar findings have been reported
for the H84A mutant (Scholz et al., 2005) and an RSV MHR
mutant L171I (Cairns and Craven, 2001). Surprisingly, the WT
level of core-associated RT was not restored in either W23F or
in the suppressor mutants (Fig. 5D) and this might account for
the low level of infectivity observed in the LuSIV assay (Fig.
5B). More detailed studies of the structure and organization of
the ribonucleoprotein complex in HIV-1 cores will be needed to
fully understand the relationship between RT levels in cores, RT
function, and the ability to generate infectious particles.
Finally, we ask: “How can we explain why V26I partially
rescues the W23F mutation?” This question is especially
relevant since Val26 is partly exposed on the surface of helix
I, whereas Trp23 is buried within the hydrophobic core (Fig.
1) (Momany et al., 1996; Tang et al., 2002). Interestingly,
the NMR structure of the N-terminal domain of CA (Tang et
al., 2002) indicates that Val26 and Trp23 are actually close
to each other. Specifically, among the family of models in
the structure file (1GWP.pdb), the smallest separation
between the side chain heavy atoms of Trp23 and Val26
ranges from 3.8 to 4.7 Å, with a mean of 4.2 Å. Based on
this information, a model of the W23F/V26I structure was
constructed such that the additional non-polar methylene
group in Ile (CH–CH2–CH3), i.e., compared with Val (CH–
CH3), contacts the Phe side chain and at least partially fills
the cavity created by the W23F mutation (Fig. 7) (S.R.
Durell, personal communication).
In conclusion, we have shown that it is possible to make a
substitution in a residue critical for maintaining HIV-1 CAbetween the side chains of Trp23 and Val26 or the substituted Phe23 and Ile26
l CA domain (Tang et al., 2002) demonstrates the closest approach of the Trp23
up of Met39 (yellow), which “hangs” over Trp23, is not shown. (B) W23F/V26I
23 and Val26 residues and then slightly moving the Ile26 and Met39 side chains.
tewart R. Durell (NCI, NIH).
113S. Tang et al. / Virology 359 (2007) 105–115structure and function, i.e., W23F, which results in virions with
a low level of infectivity in a single-round replication assay and
moderate loss of the WT phenotype. Since the N-terminal CA
structure is defined by stringent parameters and only rarely
accommodates even small perturbations at certain residues, it is
especially surprising that a second-site suppressor of the W23F
mutation could be isolated. These findings are novel and
demonstrate that, despite the limits imposed on assembly of
proper CA structure, HIV-1 is able to partially adapt to even
severe structural disruptions.
Materials and methods
Cell culture, transfection, and infection
HeLa cells were maintained as previously described (Tang et
al., 2001) and were transfected by using the Trans IT
transfection reagent (Mirus, Madison, WI), according to the
manufacturer's instructions. T-cell lines (H9, MT-4, Jurkat,
CEM (12D7), and CEM174) were maintained as described
(Murakami and Freed, 2000) and were transfected by using the
DEAE-dextran procedure detailed by Freed and Martin (1994).
For infection of T-cell lines, virus was obtained from the culture
fluids of HeLa or MT-4 cells transfected with pNL4-3 (Adachi
et al., 1986) or with variants having mutations in the CA coding
region. RT activity was detected by exogenous RT assay (Freed
et al., 1995).
Single-cycle infectivity assays
To measure viral infectivity, we used a single-cycle assay
(Roos et al., 2000). Equal amounts of viral particles
(106 cpm of RT activity under the conditions of our RT
assay) were used to infect LuSIV cells, which are CEM174
cells stably transfected with the firefly luciferase reporter
gene under the control of the simian immunodeficiency virus
(SIV) long terminal repeat. Some single-cycle assays were
also performed with TZM-bl cells, a HeLa cell line, which
expresses large amounts of CD4 and CCR5 and has
integrated copies of luciferase and β-galactosidase genes
under the control of the HIV-1 promoter (Derdeyn et al.,
2000; Platt et al., 1998; Wei et al., 2002). LuSIV cells
(originally from Drs. J.W. Roos and J.E. Clements) and
TZM-bl cells (originally from Dr. John Kappes, Dr. Xiaoyun
Wu, and Tranzyme, Inc.) were obtained through the AIDS
Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH.
Plasmids and site-specific mutagenesis
The cloning strategy used for introducing site-specific
mutations into the CA coding region in pNL4-3 followed the
procedures described by Tang et al. (1999). Detailed informa-
tion about the primers and cloning procedures used for the
construction of mutations at residues Trp23 and Phe40 of HIV-1
CA, as well as the single mutations V26I and R154K are
available upon request. The sequences of all CA mutants wereconfirmed by sequencing performed by the Biopolymer Lab
(University of Maryland, College Park, MD). Plasmid DNAs
were prepared with a QIAFilter Maxi Kit (Qiagen) or by
Lofstrand.
Analysis and construction of revertant clones
In the long-term replication experiments, genomic DNA
(template for PCR) was extracted from infected MT-4 cells
collected at the virus replication peak, using a QIAamp DNA
Mini Kit (Qiagen). A 1.3-kb fragment of viral DNA represent-
ing almost the entire HIV-1 gag region, i.e., between the BssHII
and ApaI sites of pNL4-3 (nt 701–2018) (GenBank accession
number M19921), was amplified with PCR SuperMix (Invitro-
gen). The primer sets used were as follows: JL392 (forward
primer, 5′-GCT TGC TGA AGC GCG CAC GGC, nt 701 to
721); and JL569 (reverse primer, 5′-TCC TAG GGG CCC TGC
AAT TTT TGG, nt 2018 to 1994). PCR products were purified
using the QIAQuick PCR Purification Kit (Qiagen) and
sequenced.
To construct the revertant clones, PCR products containing
the double mutation W23F/V26I or the triple mutation W23F/
V26I/R154K were digested with BssHII and ApaI. The resulting
fragments were then inserted into the pNL4-3 vector cut with
the same enzymes. For construction of the double mutants
W23F/R154K and V26I/R154K, W23F, V26I, and R154K,
plasmid DNAs were digested with BssHII and SpeI. Ligation of
fragments containing the W23F and R154K mutations,
respectively, produced CA mutant W23F/R154K, whereas
ligation of fragments containing V26I and R154K, respectively,
yielded CA mutant V26I/R154K.
Western blot analysis of WT and mutant viral proteins
The Western-Star chemiluminescence detection system
(TROPIX Inc., Bedford, MA) was used for the analysis. The
densities of the protein bands were quantified with a laser
densitometer by using a model PDS1-P90 instrument from
Molecular Dynamics Inc., Sunnyvale, CA. AIDS patient sera
were obtained from the AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH. The identity of
individual viral protein bands was confirmed with specific
antisera. Akira Ono, Department of Microbiology and Immu-
nology, University of Michigan Medical School, Ann Arbor, MI
(formerly at the HIV Drug Resistance Program, NCI at
Frederick, Frederick, MD) kindly provided rabbit anti-HIV
CA antibody. Rabbit anti-CypAwas a generous gift from David
Ott, SAIC Frederick, Inc., NCI at Frederick, Frederick, MD.
Rabbit anti-HIV IN and RT antibodies have been described in a
previous report (Klutch et al., 1998).
Transmission electron microscopy
Preparation of HeLa and MT-4 cells transfected with WT
and mutant virions for examination by electron microscopy
was performed as described previously (Freed and Martin,
1994; Tang et al., 2001). Images shown in Fig. 3 illustrate
114 S. Tang et al. / Virology 359 (2007) 105–115representative particles seen in at least eight to ten thin sections
per sample.
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